The Interaction Between Appetite Hormones
1 other identifier
interventional
58
1 country
2
Brief Summary
Glucagon Like Peptide (GLP) -1 affects metabolic response corrected for weight change
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable obesity
Started Sep 2011
Typical duration for not_applicable obesity
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
March 17, 2014
CompletedFirst Posted
Study publicly available on registry
March 21, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2014
CompletedJuly 8, 2014
July 1, 2014
2.6 years
March 17, 2014
July 4, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Change in hormone level corrected for weight change
Baseline and week 52
Study Arms (2)
GLP-1
EXPERIMENTALGLP-1 and low calorie diet
Control
EXPERIMENTALlow calorie diet
Interventions
Eligibility Criteria
You may qualify if:
- BMI \> 30 and \< 40 (kg/m2)
- Healthy
You may not qualify if:
- Other known illness
- Medicine that affects glucose- and lipid metabolism, appetite or food intake
- Pregnancy
- Breast feeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Copenhagenlead
- The Danish Medical Research Councilcollaborator
Study Sites (2)
University of Copenhagen
Copenhagen, 2200, Denmark
Hvidovre University Hospital
Hvidovre, 2650, Denmark
Related Publications (3)
Brethvad AO, Zakariassen HL, Holt J, Lundgren JR, Jakobsen A, Hartmann B, Lehmann EW, Kissow H, Holst JJ, Madsbad S, Torekov SS, Holst B. Increased meal-induced neurotensin response predicts successful maintenance of weight loss - Data from a randomized controlled trial. Metabolism. 2023 Jun;143:155534. doi: 10.1016/j.metabol.2023.155534. Epub 2023 Mar 16.
PMID: 36933790DERIVEDAkawi N, Checa A, Antonopoulos AS, Akoumianakis I, Daskalaki E, Kotanidis CP, Kondo H, Lee K, Yesilyurt D, Badi I, Polkinghorne M, Akbar N, Lundgren J, Chuaiphichai S, Choudhury R, Neubauer S, Channon KM, Torekov SS, Wheelock CE, Antoniades C. Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease. J Am Coll Cardiol. 2021 May 25;77(20):2494-2513. doi: 10.1016/j.jacc.2021.03.314.
PMID: 34016263DERIVEDIepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. J Clin Endocrinol Metab. 2015 Aug;100(8):2909-17. doi: 10.1210/jc.2015-1176. Epub 2015 Jun 4.
PMID: 26043228DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jens Holst, DMSCi
University of Copenhagen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
March 17, 2014
First Posted
March 21, 2014
Study Start
September 1, 2011
Primary Completion
April 1, 2014
Study Completion
April 1, 2014
Last Updated
July 8, 2014
Record last verified: 2014-07